Redox Directors' Expired Performance Rights Aren't the Risk — They're a Red Herring

Redox Limited (ASX:RDX) has a family that owns roughly 60 million of its own shares. Three members of that family — all directors — recently saw hundreds of thousands of performance rights disappear from their portfolios. On the surface, expired executive incentives sound like the kind of news that should make you nervous. In practice, they're the wrong signal to focus on.

The lapses came on September 11, 2026. CEO Raimond Coneliano lost 350,000 long-term incentive (LTI) rights — about half lapsed entirely, half settled in cash instead of shares. His brother Renato Coneliano lost 150,000 rights through the same mechanism. Director Richard Coneliano lost 150,000. Across the board, roughly 650,000 performance rights that were once on paper are now gone.

Here's what that actually means, and what it doesn't.

These aren't shares. They were always conditional.

Performance rights are promises that become shares only if specific long-term hurdles are met over a set timeframe. The FY24 Long-Term Incentive Plan under which these rights were granted tied vesting to performance metrics that the company hasn't disclosed in full public detail — which is common on the ASX, where hurdle formulas are often kept confidential to preserve competitive sensitivity. Some of those hurdles were met, and some rights vested. Others weren't, so they lapsed. In a few cases, the board chose to pay cash in lieu of issuing shares — a decision that reduces dilution to existing shareholders rather than increasing it.

None of this involves on-market trading, insider selling, or a loss of appetite for the stock. The Coneliano family's direct shareholdings were untouched by the announcement.

And that's the point that matters for anyone thinking about whether this company can be a reliable income stream.

Where the real ownership sits

The performance rights were never the Conelianos' main stake in Redox. Their ordinary shares are.

Raimond Coneliano holds 13 million shares directly, plus 100,000 indirectly through a trust. Renato holds 32 million directly and 31 million through closely related parties. Combined, the family controls roughly 63 million fully paid ordinary shares — and they've held them through multiple market cycles since the company listed in 2023. The Coneliano family owns approximately 65% of the company.

That's a very different picture from an executive with a small position who might sell rights at the first sign of trouble. These are the people who built the business. Redox has been a family-run chemical distributor since the 1960s. The listing didn't change the economics of who bears the downside.

When ownership of this magnitude sits behind a dividend, the question isn't whether management is motivated. It's whether the underlying cash flow can support the payout.

The cash-flow engine

For the year ended June 2026, Redox posted record revenue of $1.33 billion, up 6.9 percent. Gross profit rose 11 percent to $298 million, expanding the margin by 0.8 percentage points to 22.4 percent. Net profit after tax grew 19.2 percent to $92 million. Operating cash flow reached $88 million — up $40 million on the prior year — and free cash flow conversion improved to 62.5 percent of underlying EBITDA.

For a distributor, margins like these reflect the spread between what Redox pays for chemicals and raw materials from overseas manufacturers and what it charges Australian, New Zealand, and Southeast Asian customers. The fact that gross margin expanded while revenue grew suggests either pricing power, a shift toward higher-margin specialty products, or both.

The final dividend for FY26 was 6.5 cents per share, fully franked, paid on September 22. On a current price near A$3.40, that works out to a yield around 3.8 percent — paid out of a company that generated $88 million in operating cash on $92 million in net income, with a market cap of roughly $1.79 billion.

That's not a payout stretched beyond what the business earns. The income stream is real, and it's covered.

What would actually change the story

The expired performance rights don't signal a crisis. But a dividend investor's job isn't to dismiss every headline — it's to know what headline would matter.

The LTI lapses would be relevant only if they told you the company's performance had deteriorated enough that executive targets were consistently missed. Instead, Redox just posted its strongest results on record. The lapses may simply mean some targets were genuinely hard, which is the whole point of performance hurdles. They separate earned equity from handouts.

What would matter: a decline in gross margin that suggests the distributor's spread is being compressed. A meaningful drop in operating cash flow relative to profit, which would raise questions about whether earnings are converting to actual cash. A dividend increase that starts to outpace free cash flow. Or changes in the Coneliano family's direct shareholdings — because those 63 million ordinary shares, not the performance rights, represent the family's real wealth in this company.

None of those things has happened.

Where it fits

Redox trades at roughly 19 times earnings, slightly below the peer average for Australian industrials. It's not a yield machine in the 7 or 8 percent range — and for good reason. The dividend is genuinely covered by operating cash flow in a business that grew both revenue and margin last year. The payout ratio sits well below the level where a cut becomes a real threat.

For an income portfolio, Redox doesn't carry the top-yield headline that grabs attention on a scanner. It carries something harder to sell but more useful to own: a distribution supported by a growing cash-flow engine, behind which sits a controlling family with 65 percent of the company and every reason to keep the dividends intact.

The expired performance rights are the noise. The cash flow is the signal.